Werewolf Therapeutics to Merge with Ambros in Reverse Deal, Raising $150 Million for Rare Disease Drug
By Dr. Zubair Khalid, DVM, MS, PhD ·
Key Takeaways
- Werewolf Therapeutics, a publicly traded entity, is undergoing a reverse merger with Ambros Therapeutics, a private company, to facilitate Ambros's access to public capital markets.
- Ambros Therapeutics has secured $150 million in funding, which will be primarily allocated to advancing its lead rare disease drug candidate through Phase 3 clinical trials and preparing for regulatory submission.
- The strategic maneuver addresses Werewolf Therapeutics' previously announced review of strategic alternatives, effectively resolving its market positioning challenges.
- This transaction highlights the financial challenges inherent in rare disease drug development, where high costs are compounded by limited patient populations, necessitating significant capital infusion for late-stage progression.
- The reverse merger structure allows Ambros to bypass a traditional Initial Public Offering (IPO) process, leveraging Werewolf's existing public listing for capital acquisition and market presence.
Werewolf Therapeutics has ended its search for strategic alternatives. The company has agreed to merge with Ambros Therapeutics in an all-stock reverse merger. Ambros has raised $150 million in connection with the deal. The combined company will use the funds to advance its lead rare disease drug candidate through Phase 3 trials and toward a regulatory filing for approval.
Reverse mergers allow a private company to take over a public company’s listing, providing access to public markets without a traditional initial public offering. For Ambros, the deal supplies capital to support a late-stage clinical program in a rare disease, an area where development costs are high and patient populations are small. The transaction also resolves Werewolf’s months-long review of strategic options.
Source: original report